Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008

BEIJING, May 30 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a
pharmaceutical company in the People's Republic of China ("PRC"), today
reiterates its confidence in meeting the "make good" earnings target of net
income $13.1 million for the fiscal year 2008.

"With our continuous efforts in expanding our sales and distribution
channels as well as upcoming market launches for three additional products,
we remain confident in meeting our 'make good' net income target of $13.1
million for fiscal 2008," said Dr. Zhongyi Liu, Chairman, CEO and President
of Lotus Pharmaceuticals, Inc.

On February 26, 2008, Lotus raised $5 million in a private placement.
As part of the terms of the transaction, the Company's founders delivered
in the aggregate 7,500,000 shares of the Company's common stock owned by
them (the "Escrow Shares") to an escrow account. Subject to Lotus achieving
certain earnings targets in fiscal years 2007, 2008 and 2009, these Escrow
Shares shall be returned to the Company's founders. In 2007, the Company
exceeded the target net income of $8.5 million. The target for 2008 is 95%
of $13.8 million in net income after eliminating the effect of non-cash
charges associated with the private placement and adjusting for differences
in the exchange rate between Chinese Renminbi and US dollars used in the
Company's 2008 financial statements and an exchange rate of RMB 7.30 to USD
1.00. Additional information can be found in the Form 8-K filed on February
26, 2008 with the U.S. Securities and Exchange Commission in connection
with the private placement transaction.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang
Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd.
("Enze"), two pharmaceutical companies located in Beijing, China. Together,
Liangfang and Enze form the main enterprise (together, "Lotus East"), which
integrates the production, trade, sales and marketing operations of
pharmaceutical products. Lotus East has some of the most advanced
pharmaceutical-production equipments in China. The combined company has
manufacturing facilities certified by the National GMP, a portfolio of
medicines produced by Liangfang and/or Enze and a number of highly skilled
scientists on staff. Lotus East has office facilities of 2,000 square
meters, warehouse of 1,000 square meters and operates ten retail pharmacies
in the Beijing area. Lotus East engages in the business of new drug
discovery, drug manufacturing, wholesale and retail sale of medicines. For
more information, visit http://www.LotusEast.com .

Safe Harbor Statement

This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such statements involve known and unknown
risks, uncertainties and other factors that could cause the actual results
of the Company to differ materially from the results expressed or implied
by such statements, including changes from anticipated levels of sales,
future national or regional economic and competitive and regulatory
conditions, changes in relationships with customers, access to capital,
difficulties in developing and marketing new products, marketing existing
products, customer acceptance of existing and new products, and other
factors. Additional information regarding risks can be found in the
Company's Annual Report on Form 10K filed with the SEC. Accordingly,
although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, there can be no assurance that
such expectations will prove to be correct. The Company has no obligation
to update the forward-looking information contained in this press release.



For more information, please contact:

Lotus Pharmaceuticals, Inc.
Mr. Adam Wasserman, CFO
Tel: 877-801-0344
Email: info@LotusEast.com

CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Website: http://www.ccgelite.com




See Also

• Society for Translational Oncology Launches Updated Website
• VA Begins Next Phase of Combat Vet Outreach
• Insurance Advertising – Discover How Independent Insurance Agents Generate Leads
• Finding the Best Weight Loss Pills For You

Via: Healthcare